Hyponatremia: an update on current pharmacotherapy

Bibliography

• Schrier RW, Sharma S, Shchekochikhin D. Hyponatraemia: more than just a marker of disease severity? Nat Rev Nephrol 2012;9(1):37-50
   PubMed Web of Science ®Google Scholar
• Ayus JC, Krothapalli RK, Arieff AI. Treatment of symptomatic hyponatremia and its relation to brain damage. A prospective study. N Engl J Med 1987;317:1190-5
   PubMed Web of Science ®Google Scholar
• Ayus JC, Wheeler JM, Arieff AI. Postoperative hyponatremic encephalopathy in menstruant women. Ann Intern Med 1992;117:891-7
   PubMed Web of Science ®Google Scholar
• Ayus JC, Arieff AI. Chronic hyponatremic encephalopathy in postmenopausal women: association of therapies with morbidity and mortality. JAMA 1999;281:2299-304
   PubMed Web of Science ®Google Scholar
• Ayus JC, Varon J, Arieff AI. Hyponatremia, cerebral edema, and noncardiogenic pulmonary edema in marathon runners. Ann Intern Med 2000;132:711-14
   PubMed Web of Science ®Google Scholar
• Ayus JC, Achinger SG, Arieff A. Brain cell volume regulation in hyponatremia: role of sex, age, vasopressin, and hypoxia. Am J Physiol Renal Physiol 2008;295(3):F619-24
   PubMed Web of Science ®Google Scholar
• Bradley EL, Etheridge MS, Arieff AI. Causes of brain damage in patients with severe symptomatic hyponatremia: analysis of 344 patients over 30 years [abstract]. J Am Soc Nephrol 2005;16:44A
   Google Scholar
• Sushrut S, Waikar D, Mount G, Mortality after hospitalization with mild, moderate, and severe hyponatremia. Am J Med 2009;122(9):857-65
   PubMed Web of Science ®Google Scholar
• Wald R, Jaber BL, Price LL, Impact of hospital-associated hyponatremia on selected outcomes. Arch Intern Med 2010;170(3):294-302
   PubMedGoogle Scholar
• Goldsmith SR. Baroreceptor-mediated suppression of osmotically stimulated vasopressin in normal humans. J Appl Physiol 1988;65(3):1226-30
   PubMed Web of Science ®Google Scholar
• Robertson GL, Shelton RL, Athar S. The osmoregulation of vasopressin. Kidney Int 1975;10(1):25-37
   Web of Science ®Google Scholar
• Schrier RW, Berl T, Anderson RJ. Osmotic and nonosmotic control of vasopressin release. Am J Physiol 1979;236(4):F321-F332G
   PubMed Web of Science ®Google Scholar
• Schweiger TA, Zdanowicz MM. Vasopressin-receptor antagonists in heart failure. Am J Health Syst Pharm 2008;65(9):807-17
   PubMed Web of Science ®Google Scholar
• Gassanov N, Semmo N, Semmo M, Arginine vasopressin (AVP) and treatment with arginine vasopressin receptor antagonists (vaptans) in congestive heart failure, liver cirrhosis and syndrome of inappropriate antidiuretic hormone secretion (SIADH). Eur J Clin Pharmacol 2011;67:333-46
   PubMed Web of Science ®Google Scholar
• Laugwitz KL, Ungerer M, Schoneberg T, Adenoviral gene transfer of the human V2 vasopressin receptor improves contractile force of rat cardiomyocytes. Circulation 1999;99(7):925-33
   PubMed Web of Science ®Google Scholar
• Kaufmann JE, Iezzi M, Vischer UM. Desmopressin (DDAVP) induces NO production in human endothelial cells via V2 receptor- and cAMP-mediated signaling. J Thromb Haemost 2003;1(4):821-8
   PubMed Web of Science ®Google Scholar
• Kaufmann JE, Oksche A, Wollheim CB, Vasopressin-induced von Willebrand factor secretion from endothelial cells involves V2 receptors and cAMP. J Clin Invest 2000;106(1):107-16
   PubMed Web of Science ®Google Scholar
• Bernat A, Hoffmann P, Dumas A, V2 receptor antagonism of DDAVP-induced release of hemostasis factors in conscious dogs. J Pharmacol Exp Ther 1997;282(2):597-602
   PubMed Web of Science ®Google Scholar
• Nielsen S, Frokiaer J, Marples D, Aquaporins in the kidney: from molecules to medicine. Physiol Rev 2002;82(1):205-44
   PubMed Web of Science ®Google Scholar
• Goldsmith SR, Gheorghiade M. Vasopressin antagonism in heart failure. J Am Coll Cardiol 2005;46(10):1785-91
   PubMed Web of Science ®Google Scholar
• Ellison DH, Berl T. Clinical practice. The syndrome of inappropriate antidiuresis. N Engl J Med 2007;356(20):2064-72
   PubMed Web of Science ®Google Scholar
• Schrier RW. Body water homeostasis: clinical disorders of urinary dilution and concentration. J Am Soc Nephrol 2006;17:1820-32
   PubMed Web of Science ®Google Scholar
• Verbalis JG, Goldsmith SR, Greenberg A, Hyponatremia treatment guidelines 2007: expert panel recommendations. Am J Med 2007;120(11 Suppl 1):S1-21
   PubMed Web of Science ®Google Scholar
• Moritz ML, Ayus JC. 100 cc 3% sodium chloride bolus: a novel treatment for hyponatremic encephalopathy. Metab Brain Dis 2010;25(1):91-6
   PubMed Web of Science ®Google Scholar
• Koenig MA, Bryan M, Lewin JL III, Reversal of transtentorial herniation with hypertonic saline. Neurology 2008;70(13):1023-9
   PubMed Web of Science ®Google Scholar
• Ayus JC, Krothapalli RK, Arieff AI. Treatment of symptomatic hyponatremia and its relation to brain damage. A prospective study. N Engl J Med 1987;317:1190-5
   PubMed Web of Science ®Google Scholar
• Ayus JC, Arieff AI. Chronic hyponatremic encephalopathy in postmenopausal women: association of therapies with morbidity and mortality. JAMA 1999;281:2299-304
   PubMed Web of Science ®Google Scholar
• Miller PD, Linas SL, Schrier RW. Plasma demeclocycline levels and nephrotoxicity. Correlation in hyponatremic cirrhotic patients. JAMA 1980;243:2513-15
   PubMed Web of Science ®Google Scholar
• Decaux G, Andres C, Gankam K, Treatment of euvolemic hyponatremia in the intensive care unit by urea. Crit Care 2010;14(5):R184
   Web of Science ®Google Scholar
• Bichet DG. What is the role of vaptans in routine clinical nephrology? Clin J Am Soc Nephrol 2012;7(5):700-3
   PubMed Web of Science ®Google Scholar
• Soupart A, Coffernils M, Couturier B, Efficacy and tolerance of urea compared with vaptans for long-term treatment of patients with SIADH. Clin J Am Soc Nephrol 2012;7(5):742-7
   PubMed Web of Science ®Google Scholar
• Sawyer WH, Pang PK, Seto J, Vasopressin analogs that antagonize antidiuretic responses by rats to the antidiuretic hormone. Science 1981;212(4490):49-51
   PubMed Web of Science ®Google Scholar
• Yamamura Y, Ogawa H, Yamashita H, Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist. Br J Pharmacol 1992;105(4):787-91
   PubMed Web of Science ®Google Scholar
• Lee CR, Watkins ML, Patterson JH, Vasopressin: a new target for the treatment of heart failure. Am Heart J 2003;146(1):9-18
   PubMed Web of Science ®Google Scholar
• Tahara A, Saito M, Sugimoto T, Pharmacological characterization of YM087, a potent, nonpeptide human vasopressin V1A and V2 receptor antagonist. Naunyn–Schmiedebergs Arch Pharmacol 1998;357(1):63-9
   PubMed Web of Science ®Google Scholar
• Hoque MZ, Arumugham P, Huda N, Conivaptan: promise of treatment in heart failure. Expert Opin Pharmacother 2009;10(13):2161-9
   PubMed Web of Science ®Google Scholar
• Konstam MA, Udelson JE. Arginine vasopressin antagonists for the treatment of heart failure and hyponatremia. Circulation 2008;118(4):410-21
   PubMed Web of Science ®Google Scholar
• Velez JC, Dopson SJ, Sanders DS, Intravenous conivaptan for the treatment of hyponatraemia caused by the syndrome of inappropriate secretion of antidiuretic hormone in hospitalized patients: a single-centre experience. Nephrol Dial Transplant 2010;25(5):1524-31
   PubMed Web of Science ®Google Scholar
• Udelson JE, Smith WB, Hendrix GH, Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 2001;104(20):2417-23
   PubMed Web of Science ®Google Scholar
• Russel S, Adams K, Shaw J. Results of a twelve-week double-blind, placebo-controlled, multicenter study of oral conivaptan to assess functional capacity in patients with class III chronic heart failure (abstract). J Card Fail 2003;9(Suppl):S60
   Google Scholar
• Yamamura Y, Nakamura S, Itoh S, OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther 1998;287(3):860-7
   PubMed Web of Science ®Google Scholar
• Rangasetty UC, Gheorghiade M, Uretsky BF, Tolvaptan: a selective vasopressin type 2 receptor antagonist in congestive heart failure. Expert Opin Investig Drugs 2006;15(5):533-40
   PubMed Web of Science ®Google Scholar
• Plosker GL. Tolvaptan. Drugs 2010;70(4):443-54
   PubMed Web of Science ®Google Scholar
• Schrier RW, Gross P, Gheorghiade M, Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006;355(20):2099-112
   PubMed Web of Science ®Google Scholar
• Berl T, Quittnat-Pelletier F, Verbalis JG, Oral tolvaptan is safe and effective in chronic hyponatremia. J Am Soc Nephrol 2010;21(4):705-12
   PubMed Web of Science ®Google Scholar
• Okita K, Sakaida I, Okada M, A multicenter, open-label, dose-ranging study to exploratively evaluate the efficacy, safety, and dose-response of tolvaptan in patients with decompensated liver cirrhosis. J Gastroenterol 2010;45(9):979-87
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Niazi I, Ouyang J, Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation 2003;107(21):2690-6
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Gattis WA, O'Connor CM, Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 2004;291(16):1963-71
   PubMed Web of Science ®Google Scholar
• Udelson JE, McGrew FA, Flores E, Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction. J Am Coll Cardiol 2007;49(22):2151-9
   PubMed Web of Science ®Google Scholar
• Udelson JE, Orlandi C, Ouyang J, Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial. J Am Coll Cardiol 2008;52(19):1540-5
   PubMed Web of Science ®Google Scholar
• Matsue Y, Suzuki M, Seya M, Tolvaptan reduces the risk of worsening renal function in patients with acute decompensated heart failure in high-risk population. J Cardiol 2013;61(2):169-74
   PubMed Web of Science ®Google Scholar
• Konstam MA, Gheorghiade M, Burnett JC Jr, Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 2007;297(12):1319-31
   PubMed Web of Science ®Google Scholar
• Gross P, Reimann D, Henschkowski J, Treatment of severe hyponatremia: conventional and novel aspects. J Am Soc Nephrol 2012;12(Suppl 17):S10-14
   Google Scholar
• Costello-Boerrigter LC, Boerrigter G, Burnett JC Jr. Pharmacology of vasopressin antagonists. Heart Fail Rev 2009;14(2):75-82
   PubMed Web of Science ®Google Scholar
• Palm C, Pistrosch F, Herbrig K, Vasopressin antagonists as aquaretic agents for the treatment of hyponatremia. Am J Med 2006;119(7 Suppl 1):S87-92
   Google Scholar
• Soupart A, Gross P, Legros JJ, Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2-receptor antagonist. Clin J Am Soc Nephrol 2006;1(6):1154-60
   PubMed Web of Science ®Google Scholar
• Wong F, Gines P, Watson H, Effects of a selective vasopressin V2 receptor antagonist, satavaptan, on ascites recurrence after paracentesis in patients with cirrhosis. J Hepatol 2006;53(2):283-90
   Google Scholar
• Gines P, Wong F, Watson H, Effects of satavaptan, a selective vasopressin V2 receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial. Hepatology 2008;48(1):204-13
   PubMed Web of Science ®Google Scholar
• Albright JD, Reich MF, Delos Santos EG, 5-Fluoro-2-methyl-N-[4-(5H-pyrrolo[2, 1-c]-[1,4]benzodiazepin-10(11H)-ylcarbonyl)-3-chlorophenyl]benzamide (VPA-985): an orally active arginine vasopressin antagonist with selectivity for V2 receptors. J Med Chem 1998;41(14):2442-4
   PubMed Web of Science ®Google Scholar
• Chan PS, Coupet J, Park HC, VPA-985, a nonpeptide orally active and selective vasopressin V2 receptor antagonist. Adv Exp Med Biol 1998;449:439-43
   PubMed Web of Science ®Google Scholar
• Abraham WT, Decaux G, Josiassen RC, Oral lixivaptan effectively increases serum sodium concentrations in outpatients with euvolemic hyponatremia. Kidney Int 2012;82(11):1215-22
   PubMed Web of Science ®Google Scholar
• Gerbes AL, Gulberg V, Gines P, Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial. Gastroenterology 2003;124(4):933-9
   PubMed Web of Science ®Google Scholar
• Abraham WT, Shamshirsaz AA, McFann K, Aquaretic effect of lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients. J Am Coll Cardiol 2006;47(8):1615-21
   PubMed Web of Science ®Google Scholar
• Ghali JK, Orlandi C, Abraham WT; CK-LX2401 Study Investigators. The efficacy and safety of lixivaptan in outpatients with heart failure and volume overload: results of a multicentre, randomized, double-blind, placebo-controlled, parallel-group study. Eur J Heart Fail 2012;14(6):642-51
   PubMed Web of Science ®Google Scholar
• Abraham WT, Aranda JM, Boehmer JP, Rationale and design of the treatment of Hyponatremia based on Lixivaptan in NYHA Class III/IV cardiac patient evaluation (THE BALANCE) study. Clin Transl Sci 2010;3(5):249-53
   PubMed Web of Science ®Google Scholar